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ABSTRACT 
 
Vitamin D deficiency is associated with increased risk of acute respiratory infection. 
There is an excess of respiratory infections and deaths in schizophrenia, a condition where 
vitamin D deficiency is especially prevalent. This potentially offers a modifiable risk 
factor to reduce the risk for and the severity of respiratory infection in people with 
schizophrenia, although there is as yet no evidence regarding risk of Covid-19. In this 
narrative review, we describe the prevalence of vitamin D deficiency in 
schizophrenia, report the research examining the relationship between vitamin D 
levels and Covid-19  and discuss the associations between vitamin D deficiency and 
respiratory infection, including  its immunomodulatory mechanism of action. 
 
Keywords: 25 (OH) D; psychosis; antipsychotics; pneumonia; immune 
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INTRODUCTION 
In December 2019 a novel coronavirus, severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), emerged in Wuhan, Hubei province, China. The 
World Health Organisation (WHO) declared coronavirus disease 2019 (COVID-
19) a pandemic on 11th March 2020. While it is estimated that 80% of those with 
COVID-19 are asymptomatic or have self-limiting disease, the case fatality rate for 
those hospitalised with COVID-19 is 2.3%, increasing to 10.5% in those with 
cardiovascular disease, 7.3% in those with diabetes mellitus and 6% in those with 
hypertension (Wu and McGoogan, 2020). 
People with schizophrenia have an excess of physical comorbidities and reduced 
life expectancy(Hjorthøj et al., 2017), and may be an especially vulnerable group to 
COVID-19 disease and increased mortality(Kozloff et al., 2020).  Patients with 
schizophrenia have a higher burden of the risk factors identified above (Gardner-Sood 
et al., 2015; Gaughran et al., 2019; Lally, Spaducci, et al., 2019), leaving them more 
vulnerable to adverse outcomes of infection. There is also an excess of deaths from 
pneumonia and influenza in people with schizophrenia (Olfson et al., 2015a). 
Exploring possible protective factors to mitigate risk therefore is essential for this 
vulnerable patient group.  
 
Vitamin D is known to have a critical role in the immune system, influencing many 
functions of the normal immune response to pathogens.  In those who are vitamin D 
deficient immune function is disrupted in favor of a proinflammatory state. 
Dysregulated inflammation and ‘cytokine storms’ are associated with worse outcomes 
in COVID-19, contributing to the severity of acute respiratory distress syndrome 
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(ARDS) and organ dysfunction (Cao, 2020). Early data currently available only as 
preprints suggest a major effect for vitamin D status on COVID-19 outcome (Alipio, 
2020; Raharursan P., 2020). The prevalence of vitamin D deficiency in schizophrenia 
is high, therefore one potential stratagem to mitigate risk of COVID-19 in 
schizophrenia may be to optimize vitamin D concentrations. This study reviews the 
association between vitamin D deficiency and the risk of infection and provides 
suggestions for optimising vitamin D in people with schizophrenia.  
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Background 
The two main forms of vitamin D are vitamin D3, or cholecalciferol, which is formed 
in the skin after exposure to sunlight (ultraviolet B (UVB) radiation) and 
ergocalciferol, or vitamin D2, which is obtained by UV irradiation of plants or plant 
sources.  Vitamin D has a central role in bone mineralisation and its primary function 
is to aid the intestinal absorption of calcium and phosphate (Holick, 2012).  
INSERT TABLE 1 HERE 
 
There is longstanding evidence linking vitamin D deficiency with skeletal disease, 
including rickets (Holick, 2006), osteomalacia, muscle weakness (Redzic, Lewis and 
Thomas, 2013), falls, osteoporosis and fractures (Redzic, Lewis and Thomas, 2013; 
Bolland, Grey and Avenell, 2018) (Table 1). Increasing observational and 
epidemiological data have identified associations between vitamin D deficiency and 
non-skeletal diseases, including infectious diseases (Bouillon et al., 2019).  
Ecological evidence is suggestive of links between seasonal vitamin D deficiency and 
increased respiratory infection risk (Grant, 2008). Further, preliminary 
epidemiological data points to increased mortality rates from COVID-19 in 
populations living above latitude 35 degrees North, compared to those in countries 
below 35 degrees North-this coincides with those countries in which vitamin D 
deficiency is more prevalent due to inadequate sunlight exposure in winter 
months(Rhodes et al., 2020). In this narrative review, we will describe the prevalence 
of vitamin D deficiency in first episode and established psychosis, and the 
associations between suboptimal vitamin D and respiratory tract infections. We will 
provide an analysis of the potential benefits of Vitamin D supplementation as a 
preventative measure for those with schizophrenia at risk of Vitamin D deficiency 
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associated respiratory infection and COVID-19.  
 
Prevalence of vitamin D deficiency in Schizophrenia  
People with schizophrenia and other psychotic disorders are at high risk for vitamin D 
deficiency. A cross sectional study of community based patients in the UK identified 
that 90% of people with established psychosis had suboptimal levels of vitamin D 
(<20ng/ml (<50nmol/L)), with a vitamin D deficiency (<10ng/ml (<25nmol/L)) rate 
of 50%, much higher than the rate of 15% rate in the UK general population (Ruston 
et al., 2004). Rates of vitamin D deficiency of 49% were identified in an UK hospital 
population of patients with schizophrenia (Patel and Minajagi, 2018). Comparable 
vitamin D deficiency rates have been identified in first episode psychosis (Lally, 
Ajnakina, et al., 2019), with the risk of vitamin D deficiency in individuals with FEP 
being 3-fold higher than in their age, gender and ethnicity matched controls (Crews et 
al., 2013). Consequences of low vitamin D, including the relationship with infection 
risk in this population are unclear as of yet and require further research. 
 
Vitamin D and respiratory infection risk 
There is an inverse relationship between serum vitamin D concentrations and risk of 
acute respiratory tract infections (Martineau et al., 2017). A recent meta-analysis of 
eight observational studies (n=21,000) identified that individuals with a vitamin D 
level <20ng/ml (i.e. <50nmol/l) had a 64% increased risk of community-acquired 
pneumonia(Zhou et al., 2019).  
There is evidence that vitamin D supplementation improves immune function and 
reduces the risk of respiratory infection, with higher vitamin D levels reducing the 
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severity of influenza and respiratory infections(Grant and Giovannucci, 2009; 
Martineau et al., 2017, 2019; Gruber-Bzura, 2018; Huang et al., 2020). A meta-
analysis of individual participant data from 25 randomised controlled trials, reporting 
on 10,933 participants, found that vitamin D supplementation was well tolerated and 
provided modest protection against acute respiratory tract infections (adjusted OR 
0.88; 95% confidence interval (CI) 0.81- 0.96) (Martineau et al., 2017). The effects of 
vitamin D supplementation are more significant in those with vitamin D deficiency, 
with vitamin D supplementation reducing the risk of acute respiratory 
infection(Martineau et al., 2017). This is relevant to people with schizophrenia, the 
majority of whom have suboptimal vitamin D concentrations. This raises the 
possibility that vitamin D supplementation may not only provide skeletal benefits, but 
may contribute to protection against and reduction in the severity of respiratory 
infections, which may extend to SARS-COV2.   
Mechanism 
Observational studies have identified associations between suboptimal vitamin D 
levels and increased respiratory infection risk, including SARs-COV2 infection 
(Alipio, 2020; Lau et al., 2020), but do not attribute causation. There is, however, pre-
clinical data providing mechanistic evidence of how vitamin D impacts on risk for 
viral infections(Grant et al., 2020).  
Vitamin D function in the normal immune response 
The availably of adequate serum concentration of 25(OH)D is important in mounting 
an immune response and enhancing immunomodulation, while the absence of 
adequate vitamin D may lead to an aberrant response to pathogens or autoimmunity 
(Lang et al., 2013).  The majority of immune cells express vitamin D receptor (VDR), 
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and vitamin-D has a role in immunomodulation, influencing antigen presentation, 
innate immunity and T-cell function (Lang and Aspinall, 2017). Vitamin D also 
affects the expression of Angiotensin Converting Enzyme 2 (ACE2), the functional 
receptor of which has been identified as the entry site for the SARS-CoV-2 (Lu et al., 
2020; Walls et al., 2020).  
 
 
Activated Vitamin D (1,25-dihydroxyvitamin D (1,25(OH)2D)) has a role in both 
innate and adaptive immunity. Macrophages and dendritic cells express VDR, and 
their function is responsive to circulating activated vitamin D (Chun et al., 2014). In 
response to a pathogen challenge macrophages express increased VDR and 1α-
hydroxylase (CYP27B1) which then converts biologically inert vitamin D to its active 
form. The binding of VDR also inhibits the production of proinflammatory cytokines 
(Lang and Aspinall, 2017). Vitamin D has been shown to inhibit the development of 
pro-inflammatory Th17 cells and initiate the expression of regulatory T cells which 
suppress inflammation and defend against autoimmunity (Lang et al., 2013; 
Ghavideldarestani, Honardoost and Khamseh, 2020).  
Vitamin D Regulating Inflammation 
Vitamin D is proposed to have anti-inflammatory effects. Vitamin D supplementation 
is associated with a reduction in C-reactive protein (CRP) in the general population 
(Chen et al., 2014), while in schizophrenia an inverse relationship between vitamin D 
and CRP levels was identified (Lally et al., 2016). An unblinded RCT of vitamin D 
supplementation with 50,000 IU vitamin D3 (combined with probiotic supplements) 
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in people with chronic schizophrenia demonstrated reductions in CRP and enhanced 
total antioxidant capacity compared to placebo (Ghaderi et al., 2019). Thus, vitamin 
D’s suggested anti-inflammatory effects may have a protective role against severity of 
acute respiratory infection in COVID-19. 
An animal model study identified beneficial effects of calcitriol, the biologically 
active form of vitamin D, in lipoplysccacaride (LPS) induced lung injury. LPS is a 
glycoprotein with potent proinflammatory effects, inducing a strong inflammatory 
state and specifically damaging pulmonary vascular endothelial cells, resulting in 
acute lung injury and acute respiratory distress syndrome (Xu et al., 2017). The 
mechanism by which calcitriol produced these beneficial effects was via manipulation 
of the renin angiotensin system (RAS), balancing the opposing effects of ACE and 
ACE2 in favour of low endovascular permeability. 
Optimising serum 25 (OH) D concentration is associated with responsive 
downregulation via induction of regulatory T cells and regulation of cathelicidin-
encoding gene expression (Lang and Aspinall, 2017; Cao, 2020; Mccartney and 
Byrne, 2020). Cathelicidins are stimulated by infection to produce powerful cytokines 
including IL-1, IL-6 and INF gamma, Vitamin D has a role in regulating this 
proinflammatory process (Lang and Aspinall, 2017). The immunomodulatory effect 
of vitamin D could therefore attenuate some of the downstream inflammatory 
sequalae associated with poor clinical outcome in severe respiratory illnesses 
including COVID-19 infection. These include persistent IL-6 elevation and prolonged 
interferon gamma (INFγ) response as well as high levels of other proinflammatory 
cytokines, a state termed “cytokine storm” (Cao, 2020). 
Vitamin D and COVID-19 Host Cell Invasion 
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The ACE 2 receptor has been identified as the primary site for host cell invasion for 
COVID-19. ACE 2 is expressed in the airway epithelia and lung parenchyma, as well 
as digestive system organs. ACE 2 converts angiotensin II (Ang II) to angiotensin 1-7, 
which acts as a vasodilator with a regulatory role in the RAS. Vitamin D may 
suppress RAS activity via inhibition of renin and the ACE/Ang II/AT1R cascade 
(Ghavideldarestani, Honardoost and Khamseh, 2020). In the absence of adequate 25 
(OH)D serum concentration, this function can become less efficient, potentially 
contributing to effects such as increased inflammation and thrombotic events (Xu et 
al., 2017).  
In Middle Eastern Respiratory Syndrome(MERS) 2, a molecular virulence 
mechanism including dipeptidyl peptidase-4 receptor (DPP-4/CD26) binding was 
identified. While the DPP-4/CD26 receptor has not been confirmed as a target for 
COVID-19, the genetic similarity of Mers 2 and COVID-19 (Walls et al., 2020), 
justifies considering this receptor a putative secondary adhesion molecule for 
COVID-19 host cell invasion (Mccartney and Byrne, 2020). In pre-clinical models 
correction of Vitamin D deficiency is associated with reduced DPP-4/CD26 receptor 
expression(Komolmit et al., 2017).   
(INSERT FIGURE 1 HERE) 
Summary  
The mechanisms by which vitamin D exerts its role in the immune system are 
multifactorial (Figure 1).  Low serum vitamin D concentration seems to be associated 
with inhibition of normal immunomodulatory function in favour of  proinflammatory 
state. Inadequate vitamin D levels may result in less efficient macrophage function 
and antigen presentation. Low vitamin D may therefore potentially contribute to a 
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delayed or dysregulated response to the body’s initial contact with SARS-CoV-2 or 
impede the mounting of an appropriate defence in established SARS-CoV-2 infection. 
 
 
Vitamin D Optimisation Strategies  
Vitamin D is mainly acquired from sunlight exposure, with a smaller amount gained 
from dietary sources (approximately 10%).  Although there is variation in definition 
of vitamin D deficiency (table 1), in Ireland, approximately 50% of both older (>55 
years) and adult age populations have vitamin D insufficiency (<50nmol/L) (Laird 
and Anne Kenny, 2020) and people with schizophrenia are a high-risk group for 
vitamin D deficiency (See table 2).  
INSERT TABLE 2 HERE 
The current recommendation for the prevention of vitamin D deficiency in adults in 
Ireland is daily vitamin D3 supplementation of 5ug (200IU) and 10 -15 ug (400-600 
IU/day) for the high risk groups according to healthy eating guidelines set out by The 
Food Safety Authority of Ireland (Food Safety Authority of Ireland, 2011). There is a 
differential dose response to vitamin D, with lower doses such as 400 IU-600 IU/day 
more suited to prevent vitamin D deficiency, while higher doses are required to treat 
vitamin D deficiency.  
 
Significant variations have been noted in the dose response relationship when 
attempting to supplement to achieve sufficient serum vitamin D concentrations (Aloia 
et al., 2008). The dose response data indicates the tolerability and safety of high dose 
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vitamin D3 supplementation, with  more rapid correction of vitamin D concentrations 
and increased likelihood of attaining optimal vitamin D concentrations seen with high 
doses. Daily vitamin D intake of up to 10000IU per day is felt to be safe, and 
recommendations for up to 4000IU per day in adults have been made (Holick et al., 
2011; Ross et al., 2011). In the absence of cutaneous sunlight exposure, adult males 
are shown to require 4000IU per day to maintain vitamin D concentrations (Heaney et 
al., 2003). In a general population cohort study Vitamin D3 at 4000 IU/day was 
effective in raising serum 25(OH) D to >40ng/ml in all adults over a duration of up to 
5 months, with no safety concerns (range of vitamin D values post supplementation 
69 to 125 nmol/L) (Vieth, Chan and MacFarlane, 2001). 
There is little data on vitamin D supplementation and dose response in schizophrenia, 
meaning that recommendations are based on general population data. It is pertinent 
that some people with schizophrenia may be unable to implement strategies to ensure 
adequate vitamin D levels through sunlight exposure and outdoor activity (e.g. those 
who are hospitalised).  
In one of the few reports in mental health settings, long-term high dose vitamin D 
supplementation was prescribed for the majority of admissions to a psychiatric 
hospital in Cincinnati, Ohio with no adverse events reported (McCullough, Lehrer and 
Amend, 2019). All newly admitted patients were offered 5000IU-10000 IU vitamin 
D3 per day. Analysis of data on 36 inpatients who received 5000 IU/d for 12 months 
or longer showed an increase in the mean serum 25(OH)D concentration from 24 to 
68 ng/mL (60-170nmol/L), whereas for the 78 patients who received 10000 IU/d, 
mean concentrations increased from 25 to 96 ng/mL (62.5-240nmol/L) (McCullough, 
Lehrer and Amend, 2019).  
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Evidence from general population studies therefore indicates that higher doses of 
vitamin D supplementation may be needed (e.g. 4000 IU/day) to treat deficiency, that 
such high doses are well tolerated and that the individual response may be dependent 
on the baseline 25(OH)D concentrations (Ross et al., 2011). 
 
Potential benefits of vitamin D supplementation in schizophrenia during the 
COVID-19 pandemic 
People with schizophrenia have an increased prevalence of pneumonia and respiratory 
tract infections (Dzahini et al., 2018) with associated excess mortality, with a 
standardised mortality ratio (SMR) from influenza and pneumonia of 7.0 compared to 
the general population (Olfson et al., 2015b). Observational data shows that low 
serum vitamin D levels, and particularly vitamin D deficiency, are associated with a 
higher incidence of acute respiratory tract infections (Pham et al., 2019) and an 
increase in respiratory symptoms in adult populations (Mulrennan et al., 2018; Hong 
et al., 2020) 
To date there is no evidence of a specific effect of vitamin D for the treatment or 
prevention of COVID-19 (Lee J., van Hecke O., 2020). The recommendation remains 
that clinicans should treat vitamin D deficiency irrespective of any link with 
respiratory infection (Lee J., van Hecke O., 2020). 
However, data relating to this question is emerging at pace. Preliminary reports have 
shown inverse correlations between serum vitamin D concentrations and more severe 
respiratory infections and mortality due to SARS-Cov2, with populations that are 
deficient (<30nmol/L) being most at risk (Alipio, 2020; Ilie, Stefanescu and Smith, 
2020; Lau et al., 2020; Raharursan P., 2020). On the other hand, an early analysis of 
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UK Biobank data found no association between vitamin D levels taken in 2006-2010 
and subsequent infection with COVID-19 (Hastie et al., 2020). 
Significant effects of vitamin D supplementation in reducing the risk of non-COVID-
19 respiratory tract infections for those with lower vitamin D levels were identified in 
a systematic review of seven meta-analyses of 30 RCTs  (Rejnmark et al., 2017).  A 
meta-analysis of 11 RCTs of 5389 patients found that vitamin D supplementation was 
associated with a 40% reduction in the risk for ARTIs (Bergman et al., 2013).  
Subgroup analysis found that daily administration of vitamin D3 was significantly 
associated with a reduction in ARTIs compared to less frequent administration, and 
with no effect seen for once monthly bolus administration (Bergman et al., 2013).  An 
RCT in 124 subjects found a significantly increased probability of remaining free 
from respiratory tract infections and fewer respiratory tract infections in those 
subjects treated with 4000 IU Vitamin D 3 per day compared to a placebo treated 
group (Bergman et al., 2015).  
Vitamin D supplementation in Schizophrenia 
There is a paucity of data on vitamin D supplementation in schizophrenia, with two 
RCTs investigating effects of vitamin D3 supplementation on psychotic symptoms, 
cognition and cardiometabolic outcomes (Krivoy et al., 2017; Ghaderi et al., 2019), 
and one further RCT underway (Gaughran et al., 2020), but none investigating the 
effects in respiratory infections.  
People with schizophrenia are more likely to have vitamin D deficiency or 
insufficiency(Lally et al., 2016; Adamson et al., 2017; Zhu et al., 2020). A small 
cross sectional study in clozapine treated patients identified inverse correlations 
between vitamin D concentrations and the pro inflammatory interleukin-6 (IL-6), 
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possibly indicative of immunomodulatory effect of vitamin D in this population 
(Krivoy et al., 2020). However, there is insufficient evidence to stratify vitamin D 
supplementation, given that  suboptimal vitamin D concentration are the norm in this 
population. 
When considering vitamin D testing an initial presumptive diagnosis of insufficiency 
could be made, as is the case for high risk groups in the general population, based on 
risk factors, without the need for (expensive) testing of vitamin D levels unless 
symptomatic (Burton et al., 2010; Lally and Gaughran, 2019). Indeed some patients 
with active psychosis may decline testing and need to be treated presumptively, taking 
any safety precautions into account. In the longer-term, the ideal approach to Vitamin 
D supplementation in people with schizophrenia may be ensuring prophylactic 
administration in line with national guidelines. However, standard recommendations 
for vitamin D supplementation may be inadequate to normalise vitamin D levels in 
this group, who may be unable to implement lifestyle changes to enhance outdoor 
activity and vitamin D synthesis. It may therefore be important to take levels to assess 
the effect of supplementation. 
Furthermore, current vitamin D treatment recommendations are to maintain vitamin D 
concentrations for the purpose of maintaining skeletal health.  It is unclear, however, 
what the optimal levels are for protection against respiratory and viral infections. 
Observational data indicates that 70-90% of those with schizophrenia have vitamin D 
concentrations below the threshold (50nmol/L) (Lally et al., 2016; Zhu et al., 2020) at 
which respiratory tract infection risk is known to increase (Pham et al., 2019). 
Lifestyle advice should be offered to all patients, and education that the best source 
for vitamin D is sensible levels of sunlight exposure. Spending 10-15 minutes in the 
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sunlight at least twice a week, with face and arms exposed, will suffice to ensure 
adequate vitamin D levels(Nowson et al., 2012), bearing in mind however that some 
psychotropic medications are associated with photosensitivity. 
In treating vitamin D deficiency, frequency of administration seems to be relevant. A 
meta-analysis of individual patient data identified that the protective effect of vitamin 
D in respiratory tract infections was significantly greater in those receiving daily or 
weekly doses compared to larger, less frequent bolus doses, with the effects strongest 
in those with vitamin D deficiency (<25nmol/L) who received daily or weekly doses 
(Martineau et al., 2017).  
In patients with schizophrenia, most studies have shown suboptimal vitamin D levels, 
including in community patients. For these patients, in the absence of contra-
indications (see below), 4000 IU daily of Vitamin D 3 (with a lower dose of 2000IU 
in the elderly) may be needed for a period of at least 4 weeks and up to a maximum of 
12 weeks. A maintenance regimen could then be initiated guided by levels. A four 
week period of 4000IU daily vitamin D supplementation may suffice in the Spring 
and Summer months in European countries, as there remains potential for cutaneous 
vitamin D synthesis in the summer months. A longer period of supplementation may 
be more appropriate in the Autumn and Winter months (up to 12 weeks). These 
recommendations may be more relevant to inpatients and those in long term care 
residential facilities, settings in which increased morbidity and mortality secondary to 
level of COVID-19 have been identified.  
In adults with vitamin D deficiency, vitamin D3 supplementation will not lead to a 
normalizing of 25 (OH) D concentrations until an 8-12 week period of adequate 
dosing is complete, so vitamin D levels should not be checked for at least 12 weeks 
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after treatment initiation. It is appropriate to check baseline serum calcium and at 4 
weeks to assess for hypercalcaemia and an unmasked primary hyperparathyroidism. 
Caution or referral for specialist opinion is recommended if there is evidence or a 
history of hypercalcaemia, a history of granulomatous disorders (Sarcoidosis, 
tuberculosis), a history of lymphoma, a history of renal calculi or renal impairment 
with eGFR <60mls/min. Nephrology advice is recommended for those with renal 
impairment, as 1,25 dihydroxyvitamin D may be required.  
 
 
Vitamin D Toxicity 
While rare, Vitamin D toxicity can cause severe hypercalcaemia when ingested at 
excessive amounts over a long period of time(Heaney et al., 2003). Serum 25(OH) D 
concentrations would need to exceed 150 ng/mL (375 nmol/l) before toxicity may 
become an issue, and the risk of hypercalcaemia is mitigated by ensuring vitamin D 
levels remain below 100ng/mL (250 nmol/l)(Holick et al., 2011)Cohort studies have 
shown that dosing up to 40,000 IU per day over 28 weeks did not cause an increase in 
adverse effects, and supplementation at 5500IU for 20 weeks did not raise serum 
concentrations above 160nmol/L (Holick et al., 2011). The risk for vitamin D induced 
hypercalcaemia is low, with rates of transient mild hypercalcaemia (2.56-
2.64mmol/L) of 3% and no severe hypercalcaemia in a population of healthy adults 
aged 55-70 treated with 4000 IU/day for 3 years (Billington et al., 2019) 
 
Conclusion 
With the advent of a new respiratory pandemic,  SARS-Cov2, that as of yet does not 
show consistent response to anti-viral therapy and with no vaccine immediately 
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available, it is important to optimise the underlying health state of patients with 
schizophrenia. The importance of this question in people with schizophrenia is 
amplified by their increased likelihood of exposure to infection in hospital settings 
and the high rates of COVID-19 relevant co-morbidities. Further evidence is urgently 
needed regarding the effectiveness of Vitamin D optimisation as a protective measure 
in this group. 
This review presents the evidence that optimisation of vitamin D could be beneficial 
to those with schizophrenia and other psychotic disorders through possible protective 
effects against respiratory tract infections. While specific optimisation strategies have 
not been devised for those with schizophrenia, is it reasonable to adapt the general 
population guidelines, bearing in mind the greatly enhanced likelihood of vitamin D 
deficiency in those with psychotic disorders. 
The prophylactic use of vitamin D supplementation to at risk-groups such as patients 
with schizophrenia may prove to be a cost effective measure to improve resilience to 
respiratory infections.  It is possible that this effect may extend to SARS-Cov2 
infection, although clinical trial evidence supporting this is not yet available.   
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 Table 1 : Classification of Vitamin D status for skeletal health 
For the ranges below, vitamin D status is measured in terms of 25(OH)D serum 
concentration 
Most common thresholds
 a
 
Deficiency: <50 nmol/L (20 ng/mL)  
Insufficiency: 51–74 nmol/L (21–29 ng/mL)  
Sufficiency: >75 nmol/L (>30 ng/mL) 
Most conservative thresholds
 b
 
Deficiency: <25 nmol/L (<10 ng/mL)  
Insufficiency: 25–50 nmol/L (10–20 ng/mL)  
Sufficiency: >50 nmol/L (>20 ng/mL)  
a. Holick & Chen (2008); US Institute of Medicine: Ross et al (2011).  
b. International Osteoporosis Foundation: Dawson-Hughes et al (2010).  
 
 
Figure 1: Mechanism of vitamin D anti-inflammatory and immunomodulatory function. 
 
 
 
27 
 
Table 1: Risk Factors For Developing Vitamin D Deficiency. 
Biological/Environmental  
  Pigmented skin 
Increased age  
Inadequate sunlight exposure 
Clothing concealing skin 
Sunscreen with sunscreen protection factor >30 
Dietary insufficiency in context of inadequate sunlight exposure 
Vegan (e.g. no fish in diet)  
Long term hospitalisation /institutionalisation 
Medical  
 Obesity 
Pregnancy: 
Multiple short interval pregnancy 
Fat malabsorption syndrome (Coeliac disease; Crohn’s disease; 
cystic fibrosis; liver disease) 
Short bowel syndrome 
Bariatric surgery 
Schizophrenia and other Psychiatric disorders 
Primary hyperparathyroidism 
Chronic granulomatous disorders: Sarcoidosis 
Tuberculosis 
Chronic fungal infections 
Liver disease 
Nephrotic syndrome 
 
Medication 
 
 
 Anticonvulsants: 
Carbamazepine 
Phenytoin 
Rifampicin 
Cholestyramine 
Glucocortoids 
Highly active antiretroviral treatment (HAART) 
 
 
